Search Results - "Koenig, K.B."

Which threshold for ER positivity? a retrospective study based on 9639 patients by Yi, M., Huo, L., Koenig, K.B., Mittendorf, E.A., Meric-Bernstam, F., Kuerer, H.M., Bedrosian, I., Buzdar, A.U., Symmans, W.F., Crow, J.R., Bender, M., Shah, R.R., Hortobagyi, G.N., Hunt, K.K.

“…Guidelines for the use of chemotherapy and endocrine therapy recently recommended that estrogen receptor (ER) status be considered positive if ≥1% of tumor…”
Get full text

Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer by Gonzalez-Angulo, A.M., Akcakanat, A., Liu, S., Green, M.C., Murray, J.L., Chen, H., Palla, S.L., Koenig, K.B., Brewster, A.M., Valero, V., Ibrahim, N.K., Moulder-Thompson, S., Litton, J.K., Tarco, E., Moore, J., Flores, P., Crawford, D., Dryden, M.J., Symmans, W.F., Sahin, A., Giordano, S.H., Pusztai, L., Do, K.-A., Mills, G.B., Hortobagyi, G.N., Meric-Bernstam, F.

“…Everolimus synergistically enhances taxane-induced cytotoxicity in breast cancer cells in vitro and in vivo in addition to demonstrating a direct…”
Get full text